Preferred Label : Anti-BTLA Monoclonal Antibody HFB200603;
NCIt definition : A monoclonal antibody directed against B- and T-lymphocyte attenuator (BTLA), with
potential immune checkpoint inhibitory, immunomodulating and antineoplastic activities.
Upon administration, anti-BTLA monoclonal antibody HFB200603 targets and binds to
BTLA. This prevents BTLA-mediated inhibition of T-cell activation and induces the
production of inflammatory cytokines in the tumor microenvironment (TME), leading
to antigen specific T-cell proliferation and activation of a cytotoxic T-lymphocyte
(CTL)-mediated immune response against tumor cells. BTLA, an immunoglobulin (Ig) receptor
family member expressed on activated T- and B- lymphocytes, subsets of dendritic cells
(DCs), macrophages, and nature killer (NK) cells, is an immune checkpoint involved
in suppressing immune responses. It mediates inhibition of human tumor-specific CTLs
upon engagement by tumor expressed herpesvirus-entry mediator (HVEM).;
Molecule name : HFB-200603; HFB 200603;
NCI Metathesaurus CUI : CL1907556;
Origin ID : C200566;
chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
